Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Verified site
Barcelona, Spain
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study looks at people with Hormone Receptor Positive, HER2‑low or HER2‑ultralow, unresectable or metastatic breast cancer. “Hormone receptor positive” means the cancer cells grow in response to hormones, “HER2‑low” or “HER2‑ultralow” describes a small amount of a protein on the cells, “unresectable” means the tumor cannot be removed by surgery, and “metastatic” means the cancer has spread to other parts of the body. Participants receive two medicines given by intravenous infusion (the drug is slowly delivered into a vein). The two drugs are Patritumab deruxtecan (also called HER3‑DXd) and Trastuzumab deruxtecan (also called T‑DXd), which are designed to target specific proteins on the cancer cells.
The purpose of the study is to evaluate the safety, tolerability and anti‑tumor activity of the two medicines when used together. After an initial screening, participants receive the infusions on a regular schedule and attend clinic visits for routine checks such as blood tests, heart scans, eye exams, and imaging scans to see whether the tumors shrink. The study follows participants for several months, recording any side effects and measuring how the cancer responds over time.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
14 criteria
20 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Barcelona, Spain
Madrid, Spain
Vandoeuvre Les Nancy, France
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a medicine that combines a laboratory-made antibody with a chemotherapy drug. The antibody part is designed to find and attach to a protein called HER3 that is often found on breast cancer cells. Once it binds, the attached chemotherapy is released directly into the cancer cell, helping to kill it while trying to limit damage to normal cells. In this study, patritumab deruxtecan is being given together with another drug to see how safe it is, how well patients can tolerate it, and whether it helps shrink or stop the growth of breast tumors that have low levels of HER2.
is another medicine that links an antibody to a chemotherapy agent. Its antibody is made to target a protein called HER2, which can be present in small amounts on some breast cancer cells. By attaching to HER2, the drug delivers the chemotherapy straight to the cancer cells, aiming to destroy them while sparing healthy tissue. In this trial, trastuzumab deruxtecan is used together with patritumab deruxtecan to evaluate its safety, how well patients tolerate it, and its ability to fight tumors in people with hormone‑receptor‑positive, HER2‑low or HER2‑ultralow breast cancer that cannot be removed by surgery or has spread.
This medication is given by intravenous infusion as a clear solution prepared for infusion. It is currently an investigational drug being studied in clinical trials and has not yet received regulatory approval. It is being tested for use in hormone‑receptor‑positive, HER3‑expressing breast cancers that are HER2‑low or HER2‑ultralow and cannot be removed by surgery. The drug works by attaching an antibody that seeks out the HER3 protein on cancer cells and then releases a chemotherapy payload that stops DNA replication, classifying it as an HER3‑directed antibody‑drug conjugate.
This medication is also administered as an intravenous infusion of a solution for infusion. It is an approved therapy in many countries for HER2‑positive metastatic breast cancer and is now being studied in HER2‑low breast cancer. It targets the HER2 protein on cancer cells and delivers a topoisomerase I inhibitor that interferes with DNA replication, leading to cancer cell death. It belongs to the class of HER2‑directed antibody‑drug conjugates.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.